MiNK Therapeutics, Inc.INKTNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank0
3Y CAGR-37.5%
5Y CAGR-9.9%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-37.5%/yr
Annual compound
5Y CAGR
-9.9%/yr
Recent deceleration
Percentile
P0
Near historical low
vs 5Y Ago
0.6x
Contraction
Streak
3 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$5.65M-10.8%
2024$6.34M-59.1%
2023$15.49M-33.0%
2022$23.12M+65.5%
2021$13.97M+46.9%
2020$9.51M-51.6%
2019$19.65M-